Strand Therapeutics

mRNA startup Strand Therapeutics lands $52M to “program” new cancer therapies

Messenger RNA therapies are coming in many forms and Strand Therapeutics is developing “next generation” treatments that can be programmed with features and functions, similar to how software code is written. Led by CEO Jacob Becraft, the startup has raised $52 million to support its R&D.

By Frank Vinluan

BioPharma

Among Covid-19 vaccine technologies, mRNA represents faster, easier approach, some experts say

There are multiple platforms for developing vaccines against the SARS-CoV-2 virus, including messenger RNA, DNA and molecular clamp. Moderna said last week that it had dosed the first patient in its Phase I mRNA vaccine trial.

By Alaric DeArment

mRNA startup Strand Therapeutics lands $52M to “program” new cancer therapies

Among Covid-19 vaccine technologies, mRNA represents faster, easier approach, some experts say

Market Trends to Watch for Health Systems and Their Specialty Pharmacies